Poitiers

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Amyloidosis2 trials
• Bladder cancer2 trials
• Liver and biliary tract cancer2 trials
• Multiple myeloma2 trials
• Follicular lymphoma1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Lupus (SLE)1 trial
• Mantle cell lymphoma1 trial
• Prostate cancer1 trial
• and 1 more

Phase

• Phase 38 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Not yet recruiting5 trials
• Active, not recruiting4 trials
• Recruiting3 trials
• Completed2 trials

Lead sponsor

• AstraZeneca10 trials
• Alexion Pharmaceuticals, Inc.2 trials
• Arcus Biosciences, Inc.1 trial
• Daiichi Sankyo1 trial

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· Phase 3· AstraZeneca· Source

• Recruiting

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· Phase 3· AstraZeneca· Source

• Recruiting

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· Phase 2/3· Daiichi Sankyo· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  Observational Study Protocol: LIVER-R

  NCT06252753· AstraZeneca· Source

• Active, not recruiting

  PRostate Olaparib Real World Evidence Study

  NCT06031805· AstraZeneca· Source

• Active, not recruiting

  Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

  NCT05103605· AstraZeneca· Source

• Active, not recruiting

  Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

  NCT03875235· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Multiple myeloma2 recruiting
• Amyloidosis1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

  NCT05329766· Phase 2· Arcus Biosciences, Inc.· Source

• Completed

  Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  NCT05008055· Phase 2· AstraZeneca· Source